Vaccination recommendations for patients with neuromuscular disease

Esposito, Susanna; Bruno, Claudio; Berardinelli, Angela; Filosto, Massimiliano; Mongini, Tiziana; Morandi, Lucia; Musumeci, Olimpia; Pegoraro, Elena; Siciliano, Gabriele; Tonin, Paola; Marrosu, Gianni; Minetti, Carlo; Servida, Maura; Conforti, Giorgio; Scapolan, Silvia; Ansaldi, Filippo; Vianello, Andrea; Castaldi, Silvana; Principi, Nicola; Toscano, Antonio; Moggio, Maurizio

doi:10.1016/j.vaccine.2014.09.003

Cited by 19 publications

(14 citation statements)

References 55 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…At present, the CDC limits its recommendation to live attenuated vaccines, which are contraindicated for patients with chronic neurological disorders and patients taking immunosuppressant medications due to their higher risk of severe complications. 3 17 Our findings provide important information for reassessing the guidelines relating to influenza vaccination in patients with MG.…”

Section: Discussionmentioning

confidence: 76%

The Impacts of Influenza Infection and Vaccination on Exacerbation of Myasthenia Gravis

et al. 2017

View full text Add to dashboard Cite

Background and PurposeUpper respiratory infection (URI), including influenza, may exacerbate the symptoms of myasthenia gravis (MG), which is an autoimmune disease that causes muscle weakness. There is also concern that the influenza vaccine may trigger or worsen autoimmune diseases. The objective of this study was to determine the impacts of influenza infection and vaccination on symptom severity in MG patients.MethodsPatients diagnosed with MG were enrolled from 10 university-affiliated hospitals between March and August 2015. Subjects completed a questionnaire at the first routine follow-up visit after enrolling in the study. The patient history was obtained to determine whether a URI had been experienced during the previous winter, if an influenza vaccination had been administered before the previous winter, and whether their MG symptoms were exacerbated during or following either a URI or vaccination. Influenza-like illness (ILI) was defined and differentiated from the common cold as a fever of ≥38℃ accompanied by a cough and/or a sore throat.ResultsOf the 258 enrolled patients [aged 54.1±15.2 years (mean±SD), 112 men, and 185 with generalized MG], 133 (51.6%) had received an influenza vaccination and 121 (46.9%) had experienced a common cold (96 patients) or ILI (25 patients) during the analysis period. MG symptoms were aggravated in 10 (40%) patients after ILI, whereas only 2 (1.5%) experienced aggravation following influenza vaccination. The rate of symptom aggravation was significantly higher in patients experiencing an ILI (10/25, 40%) than in those with the common cold (15/96, 15.6%, p=0.006).ConclusionsThe results of this study suggest that the potential risk of aggravating autoimmune disease is higher for ILI than for influenza vaccination, which further suggests that influenza vaccination can be offered to patients with MG.

show abstract

Section: Discussionmentioning

confidence: 76%

The Impacts of Influenza Infection and Vaccination on Exacerbation of Myasthenia Gravis

et al. 2017

View full text Add to dashboard Cite

show abstract

“…If a KD patient requires treatment with biologic drugs, it should be assumed that there may be problems of reduced immunogenicity and safety of vaccines [ 146 – 149 ]. As for the live-virus attenuated vaccines, even if there is no evidence of adverse events in the few studies available, it is believed that further studies are needed to confirm their safety; therefore, it is important that the patient receives two doses of MMR vaccine and is adequately protected even against varicella in case of no history of a natural disease for at least 1 month before the start of biological drugs [ 150 ].…”

Section: Treatment Of the Acute Phase Of Kawasaki Diseasementioning

confidence: 99%

Kawasaki disease: guidelines of the Italian Society of Pediatrics, part I - definition, epidemiology, etiopathogenesis, clinical expression and management of the acute phase

et al. 2018

Self Cite

View full text Add to dashboard Cite

The primary purpose of these practical guidelines related to Kawasaki disease (KD) is to contribute to prompt diagnosis and appropriate treatment on the basis of different specialists’ contributions in the field. A set of 40 recommendations is provided, divided in two parts: the first describes the definition of KD, its epidemiology, etiopathogenetic hints, presentation, clinical course and general management, including treatment of the acute phase, through specific 23 recommendations.Their application is aimed at improving the rate of treatment with intravenous immunoglobulin and the overall potential development of coronary artery abnormalities in KD. Guidelines, however, should not be considered a norm that limits treatment options of pediatricians and practitioners, as treatment modalities other than those recommended may be required as a result of peculiar medical circumstances, patient’s condition, and disease severity or complications.

show abstract

“…The efficacy of other vaccines is also likely to be affected 42 . High‐dose immunosuppression (prednisone >20 mg/day for >14 consecutive days, azathioprine >3 mg/kg per day, methotrexate >0.4 mg/kg per week) is more likely to affect response to vaccination than low doses 44 …”

Section: Effectiveness Of Vaccinations In Immunosuppressed Individualmentioning

confidence: 99%

Doctor—Should I get the COVID‐19 vaccine? Infection and immunization in individuals with neuromuscular disorders

2021

View full text Add to dashboard Cite

The clinical course of neuromuscular disorders (NMDs) can be affected by infections, both in immunocompetent individuals, and in those with reduced immunocompetence due to immunosuppressive/immunomodulating therapies. Infections and immunizations may also trigger NMDs. There is a potential for reduced efficacy of immunizations in patients with reduced immunocompetence. The recent vaccination program for coronavirus disease‐2019 (COVID‐19) raises several questions regarding the safety and efficacy of this vaccine in individuals with NMDs. In this Practice Topic article, we address the role of vaccine‐preventable infections in NMDs and the safety and efficacy of immunization in individuals with NMDs, with emphasis on vaccination against COVID‐19.

show abstract

Vaccination recommendations for patients with neuromuscular disease

Cited by 19 publications

References 55 publications

The Impacts of Influenza Infection and Vaccination on Exacerbation of Myasthenia Gravis

The Impacts of Influenza Infection and Vaccination on Exacerbation of Myasthenia Gravis

Kawasaki disease: guidelines of the Italian Society of Pediatrics, part I - definition, epidemiology, etiopathogenesis, clinical expression and management of the acute phase

Doctor—Should I get the COVID‐19 vaccine? Infection and immunization in individuals with neuromuscular disorders

Contact Info

Product

Resources

About